- Home
- POLE vs PHAT Comparison
POLE vs PHAT Comparison
Compare POLE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- PHAT
- Stock Information
- Founded
- POLE 2024
- PHAT 2018
- Country
- POLE United States
- PHAT United States
- Employees
- POLE N/A
- PHAT N/A
- Industry
- POLE
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- POLE
- PHAT Health Care
- Exchange
- POLE NYSE
- PHAT Nasdaq
- Market Cap
- POLE 299.8M
- PHAT 289.0M
- IPO Year
- POLE 2024
- PHAT 2019
- Fundamental
- Price
- POLE $10.25
- PHAT $3.31
- Analyst Decision
- POLE
- PHAT Strong Buy
- Analyst Count
- POLE 0
- PHAT 5
- Target Price
- POLE N/A
- PHAT $17.80
- AVG Volume (30 Days)
- POLE 88.3K
- PHAT 2.3M
- Earning Date
- POLE 01-01-0001
- PHAT 05-01-2025
- Dividend Yield
- POLE N/A
- PHAT N/A
- EPS Growth
- POLE N/A
- PHAT N/A
- EPS
- POLE N/A
- PHAT N/A
- Revenue
- POLE N/A
- PHAT $81,859,000.00
- Revenue This Year
- POLE N/A
- PHAT $201.74
- Revenue Next Year
- POLE N/A
- PHAT $114.16
- P/E Ratio
- POLE $57.91
- PHAT N/A
- Revenue Growth
- POLE N/A
- PHAT 3055.70
- 52 Week Low
- POLE $9.94
- PHAT $2.35
- 52 Week High
- POLE $11.16
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- PHAT 43.25
- Support Level
- POLE N/A
- PHAT $2.21
- Resistance Level
- POLE N/A
- PHAT $3.78
- Average True Range (ATR)
- POLE 0.00
- PHAT 0.44
- MACD
- POLE 0.00
- PHAT 0.02
- Stochastic Oscillator
- POLE 0.00
- PHAT 49.11
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.